<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889210</url>
  </required_header>
  <id_info>
    <org_study_id>18/NTB/161</org_study_id>
    <nct_id>NCT03889210</nct_id>
  </id_info>
  <brief_title>β-hydroxybutyrate, Glucose Metabolism and Prediabetes</brief_title>
  <acronym>CETUS</acronym>
  <official_title>Cross-over, Placebo-controlled, Randomized Trial of β-hydroxybutyrate in Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Auckland, New Zealand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate changes in blood glucose metabolism after administration of a
      ketone ester drink.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New-onset prediabetes is the most significant risk factor for diabetes. Clinical studies in
      healthy human volunteers have demonstrated that ketone esters lower blood glucose levels in
      both fasting and fed state.

      Participants will visit the COSMOS clinic on two occasions and will be randomly allocated to
      receive either the HVMN ketone drink or placebo, in a cross-over design. Blood samples will
      be collected sequentially every 30 minutes for up to 150 minutes. Blood samples will be
      assayed for glucose and other markers of glucose metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in plasma glucose concentration</measure>
    <time_frame>Baseline, 30, 60, 90, 120, and 150 minutes</time_frame>
    <description>Changes in plasma glucose concentration before and after administration of the intervention/placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma insulin and C-peptide concentrations</measure>
    <time_frame>Baseline, 30, 60, 90, 120, and 150 minutes</time_frame>
    <description>Changes in plasma insulin and C-peptide concentrations before and after administration of the intervention/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma concentration of gut and pancreatic hormones</measure>
    <time_frame>Baseline, 30, 60, 90, 120, and 150 minutes</time_frame>
    <description>Changes in plasma concentrations of ghrelin, incretins, cholecystokinin, gastrin-releasing peptide, peptide YY, oxyntomodulin, motilin, glucagon, amylin, pancreatic polypeptide, and vasoactive intestinal peptide before and after administration of the intervention/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in lipid profile and digestive enzymes</measure>
    <time_frame>Baseline, 30, 60, 90, 120, and 150 minutes</time_frame>
    <description>Changes in plasma concentration of triglycerides, glycerol, cholesterol, lipases before and after administration of the intervention/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma concentration of pro-inflammatory cytokines</measure>
    <time_frame>Baseline, 30, 60, 90, 120, and 150 minutes</time_frame>
    <description>Changes in plasma concentration of interleukin-1β, interleukin-6, leptin, tumor necrosis factor α, and monocyte chemoattractant protein-1 and other cytokines before and after administration of the intervention/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in plasma concentration of markers of iron metabolism</measure>
    <time_frame>Baseline, 30, 60, 90, 120, and 150 minutes</time_frame>
    <description>Changes in plasma concentration of ferritin, hepcidin, transferrin receptor before and after administration of the intervention/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with body fat phenotypes</measure>
    <time_frame>150 minutes</time_frame>
    <description>Differences in the association between rate of change in plasma glucose concentration and magnetic resonance imaging-derived visceral fat volume in the intervention/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with body fat phenotypes</measure>
    <time_frame>150 minutes</time_frame>
    <description>Differences in the association between rate of change in plasma glucose concentration and magnetic resonance imaging-derived subcutaneous fat volume in the intervention/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with body fat phenotypes</measure>
    <time_frame>150 minutes</time_frame>
    <description>Differences in the association between rate of change in plasma glucose concentration and magnetic resonance imaging-derived liver fat per centage in the intervention/placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with physical activity</measure>
    <time_frame>150 minutes</time_frame>
    <description>Differences in the association between rate of change in plasma glucose concentration and metabolic equivalents score in the intervention/placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>HVMN ketone drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HVMN ketone drink will be given in a total volume of 100 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given in a total volume of 100 ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HVMN Ketone</intervention_name>
    <description>Water-based, flavoured sport beverage</description>
    <arm_group_label>HVMN ketone drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Water, stevia, malic acid, and thickening agent</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals over 18 years

          -  Individuals diagnosed with prediabetes; defined based on the American Diabetes
             Association guidelines

          -  History of at least one episode of acute pancreatitis

          -  Written informed consent

        Exclusion Criteria:

          -  Individuals who are on a ketogenic diet or consuming nutritional ketone supplements

          -  History of cancer or chronic pancreatitis

          -  History of bariatric or gastrointestinal surgery

          -  Pregnant or breastfeeding women

          -  Individuals involved in intensive endurance training or competitive athletics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Auckland; Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Auckland, New Zealand</investigator_affiliation>
    <investigator_full_name>Max Petrov</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Ketones</keyword>
  <keyword>Prediabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

